About This Fibrosis-4 Index Calculator
This Fibrosis-4 Index Calculator is a clinical tool that computes the Fibrosis-4 Index, a validated marker for assessing the risk of advanced liver fibrosis. By using four standard parameters—age, AST, ALT, and platelet count—this calculator provides a score that helps clinicians stratify patients into low, indeterminate, or high-risk categories. It is an essential first-line screening tool in the management of chronic liver diseases like MASLD/NAFLD, helping to identify patients who may require further investigation, such as transient elastography or referral to a specialist.
The Formula Explained
The FIB-4 Index is calculated from a patient’s age and three common laboratory values. A higher score indicates a greater likelihood of advanced liver fibrosis.
$$ \text{FIB-4} = \frac{\text{Age (years)} \times \text{AST (U/L)}}{\text{Platelet Count} (10^9/\text{L}) \times \sqrt{\text{ALT (U/L)}}} $$
Clinical Interpretation & Limitations
The interpretation of the FIB-4 score is based on age-dependent cutoffs, as recommended by the 2023 AASLD guidance for NAFLD/MASLD.
| Risk Category |
FIB-4 Score (Age < 65) |
FIB-4 Score (Age ≥ 65) |
| Low Risk |
< 1.3 |
< 2.0 |
| Indeterminate Risk |
1.3 – 2.67 |
2.0 – 2.67 |
| High Risk |
> 2.67 |
> 2.67 |
Limitations
While a powerful tool, the FIB-4 Index has limitations. Its accuracy can be reduced in patients younger than 35. The score can also be confounded by conditions that acutely affect liver enzymes or platelets, such as acute viral hepatitis, alcohol binge drinking, or certain medications, without the presence of fibrosis.
Frequently Asked Questions (FAQ)
1. What is liver fibrosis?
Liver fibrosis is the excessive accumulation of scar tissue in the liver, which results from chronic inflammation and injury. Over time, severe fibrosis can progress to cirrhosis, leading to liver failure and an increased risk of liver cancer.
2. Why are the FIB-4 cutoffs different for patients 65 and older?
Liver stiffness naturally tends to increase with age. The higher low-risk cutoff for older adults (2.0 vs. 1.3) adjusts for this age-related change, improving the test’s specificity and helping to avoid misclassifying older individuals as having higher risk than they actually do.
3. What should be done for an “Indeterminate” FIB-4 score?
An indeterminate score is not a diagnosis but an indication that further testing is needed. The standard next step is typically a liver stiffness measurement, most commonly with transient elastography (FibroScan®), or another validated blood test like the ELF™ test to further clarify the risk of advanced fibrosis.
4. Can this calculator replace a liver biopsy?
No. The FIB-4 index is a noninvasive screening tool designed to help clinicians decide who needs further testing. A liver biopsy, while invasive, remains the gold standard for directly assessing the stage of liver fibrosis and is often considered for patients in the high-risk category.
5. What is NAFLD/MASLD?
NAFLD stands for Nonalcoholic Fatty Liver Disease. In 2023, major liver societies proposed a name change to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) to more accurately reflect the condition’s link to metabolic syndrome (obesity, type 2 diabetes, etc.) and to remove potentially stigmatizing language.
📖 Sources:
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. (2023). AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797-1835. PMID: 36727674.
- Sterling RK, Lissen E, Clumeck N, et al. (2006). Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 43(6), 1317-1325. PMID: 16729309.
- Shah AG, Lydecker A, Murray K, et al. (2009). Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 7(10), 1104-1112. PMID: 19523535.
⚠️ Disclaimer:
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context.
